Ribomic (TSE:4591) Research & Development: 円803.99 Mil (TTM As of Mar. 2026)


TSE:4591 Ribomic Inc TSE:4591
30 GF Score
Price 円59.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Research & Development?

Ribomic TSE:4591 +1.72% 30 Research & Development is 円803.99 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ribomic's Research & Development for the six months ended in Mar. 2026 was 円470.48 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円803.99 Mil.

Ribomic  (TSE:4591) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ribomic Research & Development Related Terms

Ribomic Research & Development Historical Data

* Premium members only.

The historical data trend for Ribomic's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Research & Development Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,482.13 1,491.24 764.33 667.69 803.99

Ribomic Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 365.05 321.61 346.08 333.51 470.48
TSE:4591
30GF Score
Ribomic Inc TSE:4591
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円803.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円803.99 Mil mean?
Ribomic (TSE:4591) has a Research & Development of 円803.99 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ribomic and its competitors.
Is Ribomic's Research & Development too high?
Ribomic's current Research & Development is 円803.99 Mil. Overall, Ribomic has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Research & Development compare to VRTX and REGN?
Ribomic's Research & Development of 円803.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ribomic and its competitors. Ribomic's current Research & Development is 円803.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Research & Development of 円803.99 Mil. The current Research & Development is 円803.99 Mil. Ribomic's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Research & Development is 円803.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
30GF Score

Get the complete analysis for TSE:4591

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円59.00
Price